| Literature DB >> 12097383 |
Einar Martin Aandahl1, Walter J Moretto, Patrick A Haslett, Torkel Vang, Tone Bryn, Kjetil Tasken, Douglas F Nixon.
Abstract
cAMP inhibits biochemical events leading to T cell activation by triggering of an inhibitory protein kinase A (PKA)-C-terminal Src kinase pathway assembled in lipid rafts. In this study, we demonstrate that activation of PKA type I by Sp-8-bromo-cAMPS (a cAMP agonist) has profound inhibitory effects on Ag-specific immune responses in peripheral effector T cells. Activation of PKA type I inhibits both cytokine production and proliferative responses in both CD4(+) and CD8(+) T cells in a concentration-dependent manner. The observed effects of cAMP appeared to occur endogenously in T cells and were not dependent on APC. The inhibition of responses was not due to apoptosis of specific T cells and was reversible by a PKA type I-selective cAMP antagonist. This supports the notion of PKA type I as a key enzyme in the negative regulation of immune responses and a potential target for inhibiting autoreactive T cells.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12097383 DOI: 10.4049/jimmunol.169.2.802
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422